Proceedings of International Conference on Applied Innovation in IT  ·  2026/03/31  ·  Vol. 14  ·  Issue 1  ·  pp. 791–798
Computational Assessment of Nanoencapsulated Liposome-Insulin for Diabetes-Associated Liver Protection
Bilal Salman Mohammed, Faris .Q. B. Alenzi, Mohanad Waheeb Mahdi, Ali Jaffar Saleem, Mohammed Waheeb Mahdi, Anaam Fuad Hussain, Arshad Mohmmed Nafie and Knight Nthebere
📄 Download PDF DOI: 10.25673/123639
Abstract
This study evaluates the therapeutic potential of nanoencapsulated liposome–insulin as an advanced drug delivery system for mitigating diabetes-associated liver dysfunction. The formulation was prepared using the solvent injection method and characterized by UV–Vis spectroscopy, Fourier-transform infrared spectroscopy (FTIR), and field emission scanning electron microscopy (FESEM), confirming successful encapsulation, structural integrity, and nanoscale particle size ranging from 45 to 177 nm. An in vivo model was established using alloxan-induced diabetic male rats divided into control, untreated diabetic, and treated groups. Liver function was assessed through serum biomarkers, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP), alongside histopathological examination. Diabetic rats exhibited significantly elevated enzyme levels, indicating hepatic damage. Treatment with liposome–insulin resulted in a marked reduction in AST and ALT levels, while ALP remained elevated. Histological findings confirmed improved hepatic architecture, reduced necrosis, and decreased inflammatory infiltration in treated animals. The observed effects are attributed to enhanced insulin stability, improved bioavailability, and more efficient cellular delivery provided by the liposomal system. These findings suggest that nanoencapsulated liposome–insulin represents a promising strategy for improving therapeutic outcomes and reducing liver complications associated with diabetes.
Keywords
Nanoencapsulated Liposome-Insulin Liver Computational Analysis.
References
  1. H. Alp, A. Sahin, P. Karabaglı, S. Karaburgu, B. Y. Sanal, and E. B. Yuksel, “Current perspective on diabetes mellitus in clinical sciences,” 2023.
  2. F. Zaccardi, D. R. Webb, T. Yates, and M. J. Davies, “Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective,” Postgraduate Medical Journal, vol. 92, no. 1084, pp. 63-69, 2016.
  3. L. Q. Abdulhameed, A. A. Sultan, and Z. M. M. Al-Mahdawi, “Homocysteine: A recent potential risk factor for type 2 diabetes mellitus patients in Diyala Province,” in 1st Diyala Int. Conf. for Pure and Applied Science (ICPAS2021), AIP Conf. Proc., vol. 2593, no. 1, p. 050004, May 2023.
  4. K. I. Aamodt and A. C. Powers, “The pathophysiology, presentation and classification of Type 1 diabetes,” Diabetes, Obesity and Metabolism, vol. 27, pp. 15-27, 2025.
  5. N. G. Forouhi and N. J. Wareham, “Epidemiology of diabetes,” Medicine, vol. 47, no. 1, pp. 22-27, 2019.
  6. C. Aloke, C. O. Egwu, P. M. Aja, N. A. Obasi, J. Chukwu, B. O. Akumadu, and I. Achilonu, “Current advances in the management of diabetes mellitus,” Biomedicines, vol. 10, no. 10, p. 2436, 2022.
  7. B. M. Abdul Latif and M. W. Mahdi Alzubaidy, “Effect of zinc oxide nanoparticles on activity of skin cancer cell line (A-375),” in 1st Diyala Int. Conf. for Pure and Applied Science (ICPAS2021), AIP Conf. Proc., vol. 2593, no. 1, p. 050003, May 2023.
  8. M. W. M. Alzubaidy and M. N. Hussain, “Biosynthetic of green zinc oxide nanoparticles with effect on cancer cell line HeLa,” Revis Bionatura, vol. 8, no. 2, p. 22, 2023.
  9. F. Kurul, H. Turkmen, A. E. Cetin, and S. N. Topkaya, “Nanomedicine: How nanomaterials are transforming drug delivery, bio-imaging, and diagnosis,” Next Nanotechnology, vol. 7, p. 100129, 2025.
  10. Y. V. Simos et al., “Trends of nanotechnology in type 2 diabetes mellitus treatment,” Asian Journal of Pharmaceutical Sciences, vol. 16, no. 1, pp. 62-76, 2021.
  11. E. B. Souto, S. B. Souto, J. R. Campos, P. Severino, T. N. Pashirova, L. Y. Zakharova, A. M. Silva, A. Durazzo, M. Lucarini, A. A. Izzo, and A. Santini, “Nanoparticle Delivery Systems in the Treatment of Diabetes Complications,” Molecules, vol. 24, no. 23, p. 4209, Nov. 2019, [Online]. Available: https://doi.org/10.3390/molecules24234209.
  12. I. R. El Maalouf, K. Capoccia, and R. Priefer, “Non-invasive ways of administering insulin,” Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 16, no. 4, p. 102478, 2022.
  13. T. M. Joseph et al., “Nanoparticles: taking a unique position in medicine,” Nanomaterials, vol. 13, no. 3, p. 574, 2023.
  14. W. Ulbrich and A. Lamprecht, “Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases,” J. R. Soc. Interface, vol. 7, suppl. 1, pp. S55-S66, Feb. 2010, [Online]. Available: https://doi.org/10.1098/rsif.2009.0285.focus.
  15. F. Rommasi and N. Esfandiari, “Liposomal Nanomedicine: Applications for Drug Delivery in Cancer Therapy,” Nanoscale Research Letters, vol. 16, no. 95, 2021, [Online]. Available: https://doi.org/10.1186/s11671-021-03553-8.
  16. S. Pande, “Liposomes for drug delivery: review of vesicular composition, factors affecting drug release and drug loading in liposomes,” Artificial Cells, Nanomedicine, and Biotechnology, vol. 51, no. 1, pp. 428-440, 2023.
  17. P. Liu, G. Chen, and J. Zhang, “A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives,” Molecules, vol. 27, no. 4, p. 1372, 2022.
  18. M. M. Hasan, M. Hamiduzzaman, I. Jahan, A. N. Hasan, and M. A. Zaman, “Formulation development, characterization and in-vitro evaluation of tamoxifen loaded liposomes,” J. Pharm. Res. Int., vol. 32, pp. 64-82, 2020.
  19. S. Reitman and S. Frankel, “A colorimetric method for the determination of serum glutamic oxalaloacetic and glutamic pyruvic transaminases,” Am. J. Clin. Pathol., vol. 28, pp. 56-59, 1957.
  20. P. R. N. Kind and E. J. King, “Estimation of plasma phosphates by determination of hydrolyzed phenol with aminantipyrine,” Clin. Path., vol. 7, pp. 322-326, 1954.
  21. H. Nsairat, D. Khater, U. Sayed, F. Odeh, A. Al Bawab, and W. Alshaer, “Liposomes: structure, composition, types, and clinical applications,” Heliyon, vol. 8, no. 5, p. e09394, May 2022, [Online]. Available: https://doi.org/10.1016/j.heliyon.2022.e09394.
  22. J. Y. Chung, J. S. Song, K. Ylaya, J. D. Sears, L. Choi, H. Cho, A. Z. Rosenberg, and S. M. Hewitt, “Histomorphological and Molecular Assessments of the Fixation Times Comparing Formalin and Ethanol-Based Fixatives,” Journal of Histochemistry & Cytochemistry, vol. 66, no. 2, pp. 121-135, Feb. 2018, [Online]. Available: https://doi.org/10.1369/0022155417741467.
  23. V. Bewick, L. Cheek, and J. Ball, “Statistics review 9: one-way analysis of variance,” Critical Care, vol. 8, no. 2, pp. 130-136, Apr. 2004, [Online]. Available: https://doi.org/10.1186/cc2836.
  24. H. Motulsky, Intuitive Biostatistics: A Nonmathematical Guide to Statistical Thinking, Oxford University Press, USA, 2014.
  25. S. Yanti, Z. W. Wu, D. C. Agrawal, and W. J. Chien, “Interaction between phloretin and insulin: a spectroscopic study,” Journal of Analytical Science and Technology, vol. 12, pp. 1-16, 2021.
  26. L. Sercombe, T. Veerati, F. Moheimani, S. Y. Wu, A. K. Sood, and S. Hua, “Advances and challenges of liposome-assisted drug delivery,” Front. Pharmacol., vol. 6, p. 286, 2015.
  27. A. Akbarzadeh et al., “Liposome: classification preparations and applications,” Nanoscale Research Letters, vol. 8, no. 1, p. 102, 2013.
  28. O. M. El-Borady, M. S. Othman, H. H. Atallah, and A. E. A. Moneim, “Hypoglycemic potential of selenium nanoparticles capped with polyvinyl-pyrrolidone in streptozotocin-induced experimental diabetes in rats,” Heliyon, vol. 6, no. 5, 2020.
  29. M. A. Kalas, L. Chavez, M. Leon, P. T. Taweesedt, and S. Surani, “Abnormal liver enzymes: A review for clinicians,” World J. Hepatol., vol. 13, no. 11, pp. 1688, 2021.
  30. H. Fikry, L. A. Saleh, D. R. Sadek, and H. A. A. Alkhalek, “The possible protective effect of luteolin on cardiovascular and hepatic changes in a metabolic syndrome rat model,” Cell and Tissue Research, vol. 399, no. 1, pp. 27-60, 2025.
  31. M. Noroozi Karimabad, P. Khalili, F. Ayoobi, A. Esmaeili-Nadimi, C. La Vecchia, and Z. Jamali, “Serum liver enzymes and diabetes from the Rafsanjan cohort study,” BMC Endocrine Disorders, vol. 22, no. 1, p. 127, 2022.
  32. F. Zhang, X. Li, and Y. Wei, “Selenium and selenoproteins in health,” Biomolecules, vol. 13, no. 5, p. 799, 2023.
  33. J. Vasiljević, J. M. Torkko, K. P. Knoch, and M. Solimena, “The making of insulin in health and disease,” Diabetologia, vol. 63, pp. 1981-1989, 2020.
  34. M. W. Mahdi, L. Q. Abdulhameed, and A. A. Sultan, “Significant iron and vitamin D deficiency and significant increase of hepcidin level in Iraqi patient with iron deficiency anemia,” Biochemical & Cellular Archives, vol. 19, no. 1, 2019.
  35. K. Moriles, M. Zubair, and S. Azer, “Alanine aminotransferase (ALT) test,” StatPearls, 2024.
  36. P. O. Alaebo, C. Onyeabo, C. E. Oriaku, G. C. Njoku, D. U. Iloanusi, and P. O. Ekwunoh, “Hepato-protective effect and lipid profile of honey on alloxan-induced diabetic rats,” Asian Journal of Research in Biochemistry, vol. 10, no. 1, pp. 16-24, 2022.
  37. G. Martemucci, C. Costagliola, M. Mariano, L. D’Andrea, P. Napolitano, and A. G. D’Alessandro, “Free radical properties, source, and targets of antioxidant consumption and health,” Oxygen, vol. 2, no. 2, pp. 48-78, 2022.
  38. M. A. Hamed, N. S. El-Rigal, M. H. Shabana, and M. E. S. Kassem, “Chemical constituents of Argyreia speciosa Fam. Convolvulaceae and its role against hyperglycemia,” Journal of Applied Pharmaceutical Science, pp. 76-84, 2011.
  39. S. I. Khater et al., “Liposome-encapsulated berberine alleviates liver injury in type 2 diabetes by promoting AMPK/mTOR-mediated autophagy and reducing ER stress: morphometric and immunohistochemical scoring,” Antioxidants, vol. 12, no. 6, p. 1220, 2023.
  40. S. S. Shetty, P. Halagali, A. P. Johnson, K. A. Spandana, and H. V. Gangadharappa, “Oral insulin delivery: Barriers strategies and formulation approaches: A comprehensive review,” Int. J. Biol. Macromol., vol. 242, p. 125114, 2023.
  41. S. Paramshetti et al., “Unraveling the in vivo dynamics of liposomes: Insights into biodistribution and cellular membrane interactions,” Life Sciences, p. 122616, 2024.
  42. I. C. Etuk, J. A. Udobang, N. O. Ebong, and J. E. Okokon, “Solanum anomalum leaf extract and fractions attenuate oxidative stress and liver injuries in alloxan-induced diabetic rats,” Biology Medicine and Natural Product Chemistry, vol. 12, no. 1, pp. 33-44, 2023.
  43. K. Makris, C. Mousa, and E. Cavalier, “Alkaline phosphatases: biochemistry, functions, and measurement,” Calcified Tissue Int., vol. 112, no. 2, pp. 233-242, 2023.
  44. R. Poupon, “Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation,” Hepatology, vol. 61, no. 6, pp. 2080-2093, 2015.
  45. M. Soytürk et al., “Turkish Gastroenterology Association, Pancreas Study Group, Chronic Pancreatitis Committee Consensus Report,” Turk. J. Gastroenterol., vol. 31, suppl. 1, pp. S1, 2020.
  46. V. Madić et al., “Polyherbal mixture ameliorates hyperglycemia, hyperlipidemia and histopathological changes of pancreas, kidney and liver in a rat model of type 1 diabetes,” J. Ethnopharmacol., vol. 265, p. 113210, 2021.
  47. A. N. Lucchesi, L. L. Cassettari, and C. T. Spadella, “Alloxan-induced diabetes causes morphological and ultrastructural changes in rat liver that resemble the natural history of chronic fatty liver disease in humans,” J. Diabetes Res., vol. 2015, p. 494578, 2015.
  48. N. K. A. W. Suputri, A. Azmijah, R. Bijanti, and M. M. Putra, “Effects of onion extract on hepar histopathology in alloxan-induced diabetic Rattus novergicus,” Medico-Legal Updates, vol. 20, pp. 383-390, 2020.
  49. Y. Zheng et al., “Alivio de la hepatotoxicidad inducida por diabetes mediante el extracto hidroalcohólico de palmera datilera en modelo de rata: Un estudio bioquímico, inmunohistoquímico y estereológico,” Int. J. Morphol., vol. 39, no. 3, pp. 876-885, 2021.
  50. B. Giri, S. Dey, T. Das, M. Sarkar, J. Banerjee, and S. K. Dash, “Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: an update on glucose toxicity,” Biomedicine & Pharmacotherapy, vol. 107, pp. 306-328, 2018.
  51. S. Tanabayeva et al., “Study of morphological changes in rat liver caused by occlusion of inferior vena cava,” Journal of Clinical and Experimental Hepatology, vol. 12, no. 6, pp. 1451-1462, 2022.
  52. L. A. Alahmari et al., “Antioxidant and antiapoptotic effects of selenium and nano selenium-loaded exosomes on hepatic dysfunction of type 1 diabetic rats,” Journal of Experimental Zoology Part A: Ecological and Integrative Physiology, vol. 343, no. 2, pp. 211-219, 2025.
  53. M. V. Goltyaev and E. G. Varlamova, “The role of selenium nanoparticles in the treatment of liver pathologies of various natures,” International Journal of Molecular Sciences, vol. 24, no. 13, p. 10547, 2023.
  54. M. M. AbouSamra, “Liposomal nano-carriers mediated targeting of liver disorders: mechanisms and applications,” Journal of Liposome Research, vol. 34, no. 4, pp. 728-743, 2024.

Proceedings of the International Conference on Applied Innovations in IT by Anhalt University of Applied Sciences is licensed under CC BY-SA 4.0  ·  This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License

ICAIIT 2026
International Conference on Applied Innovation in IT
Navigation
Publisher
ISSN2199-8876
Publisher Edition Hochschule Anhalt
Location Anhalt University of Applied Sciences
Email leiterin.hsb@hs-anhalt.de
Phone +49 (0) 3496 67 5611
Address Building 01, Room 425
Bernburger Str. 55
D-06366 Köthen, Germany
Open Access License
CC BY-SA 4.0

All works are licensed under the Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA 4.0), unless otherwise noted.

Published by ICAIIT in cooperation with Anhalt University of Applied Sciences.

© 2026 ICAIIT — International Conference on Applied Innovations in IT. Anhalt University of Applied Sciences, Köthen, Germany.
Visitors: site traffic counter